Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 34.54 | -6.70% | -2.48 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical DCPH trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 3x Volume Pace | about 14 hours ago |
| Down 1 ATR | about 15 hours ago |
| 2x Volume Pace | about 16 hours ago |
| 60 Minute Opening Range Breakdown | about 16 hours ago |
| 1.5x Volume Pace | about 16 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 12/01/2021
Deciphera Pharmaceuticals, Inc. Description
Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Development Immune System Drugs Gastrointestinal Cancer Treatments Blastoma Antineoplastic Drugs Targeted Therapy Glioblastoma Tyrosine Kinase Receptors Platelet Protein Kinase Inhibitor Gastrointestinal Stromal Tumor Glioblastoma Multiforme Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumors Tie2 Treatment For Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 68.4 |
| 52 Week Low | 33.5501 |
| Average Volume | 404,387 |
| 200-Day Moving Average | 50.68 |
| 50-Day Moving Average | 44.03 |
| 20-Day Moving Average | 44.89 |
| 10-Day Moving Average | 44.16 |
| Average True Range | 2.68 |
| ADX | 19.51 |
| +DI | 9.77 |
| -DI | 39.05 |
| Chandelier Exit (Long, 3 ATRs ) | 40.24 |
| Chandelier Exit (Short, 3 ATRs ) | 41.58 |
| Upper Bollinger Band | 51.55 |
| Lower Bollinger Band | 38.22 |
| Percent B (%b) | -0.28 |
| BandWidth | 29.69 |
| MACD Line | -1.19 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -1.2261 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 40.47 | ||||
| Resistance 3 (R3) | 40.80 | 39.15 | 39.48 | ||
| Resistance 2 (R2) | 39.15 | 37.64 | 38.99 | 39.15 | |
| Resistance 1 (R1) | 36.85 | 36.71 | 36.02 | 36.52 | 38.82 |
| Pivot Point | 35.20 | 35.20 | 34.79 | 35.03 | 35.20 |
| Support 1 (S1) | 32.89 | 33.69 | 32.07 | 32.56 | 30.26 |
| Support 2 (S2) | 31.24 | 32.75 | 31.08 | 29.93 | |
| Support 3 (S3) | 28.94 | 31.24 | 29.60 | ||
| Support 4 (S4) | 28.61 |
